GANX
NASDAQGain Therapeutics Inc.
News · 26 weeks24-67%
2025-12-142026-06-07
Mix1790d
- SEC Filings8(47%)
- Other5(29%)
- Earnings2(12%)
- Insider2(12%)
Latest news
25 items- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150 Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next ge
- SECSEC Form 10-Q filed by Gain Therapeutics Inc.10-Q - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate UpdateBETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. This is
- SECSEC Form DEFA14A filed by Gain Therapeutics Inc.DEFA14A - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECSEC Form DEF 14A filed by Gain Therapeutics Inc.DEF 14A - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the 3rd International GBA1 Meeting 2026, being held May 22-23, 2026, in Phoenix, AZ. Details of the oral presentation are as follows:Presentation Title: "An update on the development of the GCase modulator GT-02287 for Parkinson's disease"Presenter:Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of GainSession Name:In the pipeline: updates from pharma on ongoing preclinical studies and clinical
- INSIDERSEC Form 4 filed by Mack Gene4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Fuggetta Gianluca4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- SECSEC Form 10-K filed by Gain Therapeutics Inc.10-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate UpdateBETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. "We are encouraged by the progress made in 2025, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. The promising impact GT-02287 has on the cau
- PRGain Therapeutics to Present at the 38th Annual ROTH ConferenceBETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference, being held March 22-24, 2026, in Dana Point, CA. Fireside Chat Details Date: Monday, March 23, 2026 Time: 11:30 a.m. PT Access a live webcast or a replay of the fireside chat here or visit the "Investors & Media/News & Events" section of the Company's website at https://gaintherapeutics.com
- SECGain Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF glucosylsphingosine Additional MDS-UPDRS data demonstrate continued durability at day 150 of GT-02287 administration Novel chemical series, headlined by advanced lead GT-04686, is ready for IND-enabling studies for the treatment of Parkinson's disease and other neurological disorders BETHESDA, Md., March 18, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and developm
- PRGain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory UpdateInterim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial of GT-02287 in 3Q26 after submitting additional preclinical data requested by FDA in support of an IND BETHESDA, Md., March 12, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced presentations at the AD/PD ™ 2026 International Conference on Alzheimer's and Parkinson's Disease and Related Neurological D
- PRGain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceBETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25th through Thursday, February 26th. Fireside Chat Details Date: Wednesday, February 25, 2026 Time: 1:20 p.m. ET To access a replay of the fireside chat visit here or the "Investors & Media/News & Events" section of the Company'
- SECGain Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference WeekBETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference ("JPM week") including at the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corporate Access Event. Information on all events is below. The 9th Annual Sachs Neuroscience Innovation ForumDate: January 11, 2026Format: Presentation and one-on-one meetings with managemen
- PRGain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinson's disease (PD) with or without a GBA1 mutation that further supports the disease-modifying potential of GT-02287. In participants with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) at baseline, GluSph decreased by an average of 81% after 90 days of treatment with GT-02287. Elev
- PRGain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's DiseaseBETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it will host a virtual key opinion leader (KOL) event, "Understanding GCase Substrates in Parkinson's Disease: Perspectives on Biomarkers and Disease Modification, Contextualizing emerging biomarker data from the Phase 1b clinical study of GT-02287". Featured Key Opinion Leaders (KOLs) will be Roy Alcalay, M.D., M.Sc., Chief of Movement Disorders Division, Tel Aviv Sourasky Medical Center, Professor of Neurology, Tel A
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's DiseaseResults showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase modulator to PD patients, suggests increased GCase activity in the brain, which is expected to impact the progression of Parkinson's disease (PD) KOL event planned for early January to discuss the results; registration information herein BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next ge
- SECSEC Form S-8 filed by Gain Therapeutics Inc.S-8 - Gain Therapeutics, Inc. (0001819411) (Filer)
GANX FAQ
7 questionsWhat does Gain Therapeutics Inc. do?
Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases...Where does GANX stock trade?
Gain Therapeutics Inc. (GANX) is listed on NASDAQ.What sector and industry is GANX in?
Gain Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Gain Therapeutics Inc. go public?
Gain Therapeutics Inc. (GANX) completed its IPO in 2021.What are analysts saying about GANX?
Gain Therapeutics Inc. has had 4 recent analyst actions on file. The most recent action was from Scotiabank: Sector Outperform with a $1200.00 price target on 2025-03-07. Recent price targets range from $700.00 to $2100.00.What companies are similar to GANX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GANX side-by-side with any of them on Quantisnow.How can I track GANX on Quantisnow?
Quantisnow aggregates Gain Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GANX to receive live email and push alerts on every new disclosure.